WordNet

the 3rd letter of the Roman alphabet (同)c
(music) the keynote of the scale of C major
a general-purpose programing language closely associated with the UNIX operating system

PrepTutorEJDIC

carbonの化学記号
California
circa

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/02/09 23:14:49」(JST)

wiki en

For the highway, see California State Route 125.

CA-125 (cancer antigen 125, carcinoma antigen 125, or carbohydrate antigen 125) also known as mucin 16 or MUC16 is a protein that in humans is encoded by the MUC16 gene.^[1]^[2] MUC16 is a member of the mucin family glycoproteins.^[3] CA-125 has found application as a tumor marker or biomarker that may be elevated in the blood of some patients with specific types of cancers,^[4] or other benign conditions.

1 Structure
2 Function
3 As a biomarker
- 3.1 Early detection of ovarian cancer
- 3.2 Specificity and sensitivity
- 3.3 Ranges in ovarian cancer
4 Role in cancer
- 4.1 Immune system evasion
- 4.2 Metastatic invasion
- 4.3 Induced motility
- 4.4 Chemotherapy resistance
5 Discovery
6 References
7 Further reading
8 External links

Structure[edit]

Mucin 16 is a membrane associated mucin that possesses a single transmembrane domain.^[5] A unique property of MUC16 is its large size. MUC16 is more than twice as long as MUC1 and MUC4 and contains about 22,000 amino acids, making it the largest membrane associated mucin.^[6]

MUC16 is composed of three different domains:^[7]

An N-terminal domain
A tandem repeat domain
A C-terminal domain

The N-terminal and tandem repeat domains are both entirely extracellular and highly O-glycosylated. All mucins contain a tandem repeat domain that has repeating amino acid sequences high in serine, threonine and proline.^[8] The C-terminal domain contains multiple extracellular SEA (sea urchin sperm protein, enterokinase, and agrin) modules,^[9] a transmembrane domain, and a cytoplasmic tail.^[7] The extracellular region of MUC16 can be released from the cell surface by undergoing proteolytic cleavage.^[10] MUC16 is thought to be cleaved at a site in the SEA modules.^[11]

Function[edit]

MUC16 is a component of the ocular surface (including the cornea and conjunctiva), the respiratory tract and the female reproductive tract epithelia. Since MUC16 is highly glycosylated it creates a hydrophilic environment that acts as a lubricating barrier against foreign particles and infectious agents on the apical membrane of epithelial cells.^[12] Also, the cytoplasmic tail of MUC16 has been shown to interact with cytoskeleton by binding members of the ERM protein family.^[13] The expression of mucin 16 has been shown to be altered in dry eye, cystic fibrosis, and several types of cancers.^[14]

As a biomarker[edit]

CA-125 is the most frequently used biomarker for ovarian cancer detection.^[15] Medical societies including American Congress of Obstetricians and Gynecologists recommend against women with average risk of ovarian cancer having routine CA-125 screening or other screening for this cancer.^[16] Reasons for this include evidence ambiguous test results are more likely to lead to further invasive, harmful, and unnecessary health care than they are to detect ovarian cancer in women who are at average risk of developing it.^[16]

Around 90% of women with advanced ovarian cancer have elevated levels of CA-125 in their blood serum, making CA-125 a useful tool for detecting ovarian cancer after the onset of symptoms.^[17] Monitoring CA-125 blood serum levels is also useful for determining how ovarian cancer is responding to treatment (with the duration of disease-free survival correlating with the rate of fall of CA-125)^[18] and for predicting a patient’s prognosis after treatment.^[19] This is because the persistence of high levels of CA-125 during therapy is associated with poor survival rates in patients.^[19] Also, an increase in CA-125 levels within individuals in a remission is a strong predictor of the recurrence of ovarian cancer.^[20] Indeed, a rising CA-125 level may precede clinical evidence of disease relapse by an interval of 3 to 6 months.

Prognosis relates to both the initial and post-treatment CA-125 values. A preoperative value >65 U/mL suggests a poor prognosis. Persistent elevations following chemotherapy indicate a poor prognosis. The half-life of CA-125 after chemotherapy correlates with prognosis (patients with CA-125 half-life <20 days show improved survival). Time-to-normalization (rate of fall of CA-125) affects prognosis with more rapid normalization within 3 cycles of chemotherapy correlating with improved survival.^[21]

In April 2011 the UK's National Institute for Health and Clinical Excellence (NICE) recommended that women with symptoms that could be caused by ovarian cancer should be offered a CA-125 blood test.^[22] The aim of this guideline is to help diagnose the disease at an earlier stage, when treatment is more likely to be successful. Women with higher levels of the marker in their blood would then be offered an ultrasound scan to determine whether they need further tests.

In one case, elevated serum levels of CA-125 were observed in a male patient with IgE myeloma, however more cases are needed to determine the clinical significance of CA-125 in myeloma.^[23]

Early detection of ovarian cancer[edit]

The potential role of CA-125 for the early detection of ovarian cancer is controversial and has not yet been adopted for widespread screening efforts in asymptomatic women.^[24]^[25] The major issues with using the CA-125 biomarker are its lack of sensitivity, particularly for detecting early stages of ovarian cancer, and its lack of specificity, especially in premenopausal women.^[26] These limitations mean that CA-125 testing often gives false positives for ovarian cancer and puts patients through unnecessary further screening (sometimes including surgery) and anxiety.^[27] Also, these limitations mean that many women with early stage ovarian cancer will receive a false negative from CA-125 testing and not get further treatment for their condition.^[28]

Specificity and sensitivity[edit]

CA-125 has limited specificity for ovarian cancer because elevated CA-125 levels can be found in individuals without ovarian cancer. For example, while CA-125 is best known as a marker for ovarian cancer,^[29] it may also be elevated in other cancers, including endometrial cancer, fallopian tube cancer, lung cancer, breast cancer and gastrointestinal cancer.^[30] CA-125 may also be elevated in a number of relatively benign conditions, such as endometriosis,^[31] several diseases of the ovary, menstruation^[26] and pregnancy.^[32] It also tends to be elevated in the presence of any inflammatory condition in the abdominal area, both cancerous and benign,^[33] as well as in cirrhosis and diabetes mellitus. ^[34] Thus, CA-125 testing is not perfectly specific for ovarian cancer and often results in false positives.^[26]

The specificity of CA-125 is particularly low in premenopausal women because many benign conditions that cause fluctuations in CA-125 levels, such as menstruation, pregnancy, and pelvic inflammatory disease, are seen in this population.^[25]

CA-125 testing is also not perfectly sensitive for detecting ovarian cancer because not every patient with cancer will have elevated levels of CA-125 in their blood.^[35] For example, 79% of all ovarian cancers are positive for CA-125, whereas the remainder do not express this antigen at all.^[36] Also, only about 50% of patients with early stage ovarian cancer have elevated CA-125 levels, meaning that CA-125 has particularly poor sensitivity for ovarian cancer before the onset of symptoms.^[37]^[26] Poor sensitivity means that the use of CA-125 to detect ovarian cancer (especially in early stages of disease) can frequently lead to false negatives. Patients that receive false negatives are unlikely to seek further treatment for their disease.

Ranges in ovarian cancer[edit]

While this test is not generally regarded as useful for large scale screening by the medical community, a high value may be an indication that the woman should receive further diagnostic screening or treatment. Normal values range from 0 to 35 (U/mL).^[26] Elevated levels in post-menopausal women are usually an indication that further screening is necessary. In pre-menopausal women, the test is less reliable as values are often elevated due to a number of non-cancerous causes, and a value above 35 is not necessarily a cause for concern.^[25]

In a patient who is clinically selected for testing due to the presence of an adnexal/pelvic mass, CA-125 has great utility to differentiate benign from malignant processes. In a post-menopausal woman with a palpable adnexal mass and CA-125 level greater than 65 U/mL, the positive predictive value is >95% for ovarian malignancy. In patients who are not as carefully selected clinically, the utility of this test decreases, thus highlighting the need for careful clinical scrutiny.

Role in cancer[edit]

Tumor metastasis initiated by interactions between MUC16 and mesothelin.

MUC16 has been shown to play a role in advancing tumorigenesis and tumor proliferation by several different mechanisms.

Immune system evasion[edit]

One way that MUC16 helps the growth of tumors is by suppressing the response of natural killer cells, which protects the cancer cells from the immune response.^[38] Further evidence that MUC16 can protect tumor cells from the immune system is the discovery that the heavily glycosylated tandem repeat domain of MUC16 can bind to galectin-1 (an immunosuppressive protein).^[39]

Metastatic invasion[edit]

MUC16 is also thought to participate in cell-to-cell interactions that allow for the metastasis of tumor cells. This is supported by evidence showing that MUC16 binds selectively to mesothelin, a glycoprotein normally expressed by the mesothelial cells of the peritoneum (the lining of the abdominal cavity).^[40] MUC16 and mesothelin interactions are thought to provide the first step in tumor cell invasion of the peritoneum.^[41]

Mesothelin has also been found to be expressed in several types of cancers including mesothelioma, ovarian cancer and squamous cell carcinoma.^[42] Since mesothelin is also expressed by tumor cells, MUC16 and mesothelial interactions may aid in the gathering of other tumor cells to the location of a metastasis, thus increasing the size of the metastasis.^[41]

Induced motility[edit]

Evidence suggests that expression of the cytoplasmic tail of MUC16 enables tumor cells to grow, promotes cell motility and may facilitate invasion. This appears to be due to the ability of the C-terminal domain of MUC16 to facilitate signaling that leads to a decrease in the expression of E-cadherin and increase the expression of N-cadherin and vimentin, which are expression patterns consistent with epithelial-mesenchymal transition.^[43]

Chemotherapy resistance[edit]

MUC16 might also play a role in reducing the sensitivity of cancer cells to drug therapy. Overexpression of MUC16 has been shown to protect cells from the effects of genotoxic drugs, such as cisplatin.^[44]

Discovery[edit]

CA-125 was initially detected using the murine monoclonal antibody designated OC125. Drs. Robert Bast, Robert Knapp and their research team first isolated this monoclonal antibody in 1981.^[45] The protein was named “cancer antigen 125” because OC125 was the 125th antibody produced against the ovarian cancer cell line that was being studied.^[46]

References[edit]

^ Yin BW, Lloyd KO (July 2001). "Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16". J. Biol. Chem. 276 (29): 27371–5. doi:10.1074/jbc.M103554200. PMID 11369781.
^ Yin BW, Dnistrian A, Lloyd KO (April 2002). "Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene". Int. J. Cancer 98 (5): 737–40. doi:10.1002/ijc.10250. PMID 11920644.
^ Duraisamy S, Ramasamy S, Kharbanda S, Kufe D (May 2006). "Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16". Gene 373: 28–34. doi:10.1016/j.gene.2005.12.021. PMID 16500040.
^ Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998). "CA 125: the past and the future". Int. J. Biol. Markers 13 (4): 179–87. PMID 10228898.
^ Gipson IK (October 2007). "The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture". Invest. Ophthalmol. Vis. Sci. 48 (10): 4390; 4391–8. doi:10.1167/iovs.07-0770. PMC 2886589. PMID 17898256.
^ Gniewek P, Kolinski A (January 2012). "Coarse-Grained Modeling of Mucus Barrier Properties". Biophys. J. 102 (2): 195–200. doi:10.1016/j.bpj.2011.11.4010. ISSN 0006-3495. PMID 22339855.
^ ^a ^b O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L (Nov–Dec 2001). "The CA 125 gene: an extracellular superstructure dominated by repeat sequences". Tumour Biol. 22 (6): 348–66. doi:10.1159/000050638. PMID 11786729.
^ Hollingsworth MA, Swanson BJ (January 2004). "Mucins in cancer: protection and control of the cell surface". Nat. Rev. Cancer 4 (1): 45–60. doi:10.1038/nrc1251. PMID 14681689.
^ Kufe DW (December 2009). "Mucins in cancer: function, prognosis and therapy". Nat. Rev. Cancer 9 (12): 874–85. doi:10.1038/nrc2761. PMC 2951677. PMID 19935676.
^ Goodell CA, Belisle JA, Gubbels JA, Migneault M, Rancourt C, Connor J, Kunnimalaiyaan M, Kravitz R, Tucker W, Zwick M, Patankar MS (2009). "Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies". J Ovarian Res 2 (1): 8. doi:10.1186/1757-2215-2-8. PMC 2708168. PMID 19538730.
^ Palmai-Pallag T, Khodabukus N, Kinarsky L, Leir SH, Sherman S, Hollingsworth MA, Harris A (June 2005). "The role of the SEA (sea urchin sperm protein, enterokinase and agrin) module in cleavage of membrane-tethered mucins". FEBS J. 272 (11): 2901–11. doi:10.1111/j.1742-4658.2005.04711.x. PMID 15943821.
^ Perez BH, Gipson IK (November 2008). "Focus on Molecules: human mucin MUC16". Exp. Eye Res. 87 (5): 400–1. doi:10.1016/j.exer.2007.12.008. PMC 2586928. PMID 18289532.
^ Blalock TD, Spurr-Michaud SJ, Tisdale AS, Heimer SR, Gilmore MS, Ramesh V, Gipson IK (October 2007). "Functions of MUC16 in corneal epithelial cells". Invest. Ophthalmol. Vis. Sci. 48 (10): 4509–18. doi:10.1167/iovs.07-0430. PMID 17898272.
^ Bafna S, Kaur S, Batra SK (May 2010). "Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells". Oncogene 29 (20): 2893–904. doi:10.1038/onc.2010.87. PMC 2879972. PMID 20348949.
^ Suh KS, Park SW, Castro A, Patel H, Blake P, Liang M, Goy A (November 2010). "Ovarian cancer biomarkers for molecular biosensors and translational medicine". Expert Rev. Mol. Diagn. 10 (8): 1069–83. doi:10.1586/erm.10.87. PMID 21080822.
^ ^a ^b American Congress of Obstetricians and Gynecologists, "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American Congress of Obstetricians and Gynecologists), retrieved August 1, 2013 , which cites
- "Screening for Ovarian Cancer: Recommendation Statement". The Annals of Family Medicine 2 (3): 260–262. 2004. doi:10.1370/afm.200. edit
- Lin, Kenneth; Barton, Mary B. (April 2012), "Screening for Ovarian Cancer - Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement", AHRQ Publication No. 12-05165-EF-3 (United States Preventive Services Task Force), retrieved 30 August 2013
- Partridge, E.; Greenlee, A. R.; Xu, R. T.; Kreimer, C.; Williams, J. L.; Riley, T. R.; Reding, B.; Church, C. C.; Kessel, J. L.; Johnson, C.; Hill, G. L.; Fouad, S.; Buys, L. R.; Isaacs, S. S.; Andriole, T.; Ogden, S.; Chia, D.; Ragard, L. R.; Prorok, P. C.; Gohagan, J. K.; Berg, C. D. (2009). "Results from four rounds of ovarian cancer screening in a randomized trial". Obstetrics and gynecology 113 (4): 775–782. doi:10.1097/AOG.0b013e31819cda77. PMC 2728067. PMID 19305319. edit
- American College of Obstetricians; Gynecologists Committee on Gynecologic Practice (2011). "Committee Opinion No. 477: The Role of the Obstetrician–Gynecologist in the Early Detection of Epithelial Ovarian Cancer". Obstetrics & Gynecology 117 (3): 742–746. doi:10.1097/AOG.0b013e31821477db. PMID 21343791. edit
^ Gupta D, Lis CG (2010). "Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature". Nutr J 9: 69. doi:10.1186/1475-2891-9-69. PMC 3019132. PMID 21176210.
^ Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (October 1983). "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". N. Engl. J. Med. 309 (15): 883–7. doi:10.1056/NEJM198310133091503. PMID 6310399.
^ ^a ^b Göcze P, Vahrson H (April 1993). "[Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)]". Orv Hetil (in Hungarian) 134 (17): 915–8. PMID 8479736.
^ Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow RE (December 2005). "Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range". J. Clin. Oncol. 23 (36): 9338–43. doi:10.1200/JCO.2005.02.2582. PMID 16361633.
^ Mais DD, Leonard GR (2009). Quick Compendium Companion for Clinical Pathology (2nd ed.). Chicago: American Society for Clinical Pathology. p. 352. ISBN 0-89189-579-5.
^ "Women should be offered a blood test for ovarian cancer". NICE guidance. United Kingdom National Institute for Health and Clinical Excellence. 2011-04-27. Retrieved 2012-04-14.
^ Wang ML, Huang Q, Yang T (July 2009). "IgE myeloma with elevated level of serum CA125". J Zhejiang Univ Sci B. 10 (7): 559–562. doi:10.1631/jzus.B0820399. PMC 2704975. PMID 19585675.
^ Baron, JA (May 2012). "Screening for cancer with molecular markers: progress comes with potential problems". Nat. Rev. Cancer 12 (5): 1379–80. doi:10.1038/nrc3260. PMID 22495319.
^ ^a ^b ^c Fritsche HA, Bast RC (July 1998). "CA 125 in ovarian cancer: advances and controversy". Clin. Chem. 44 (7): 1379–80. PMID 9665412.
^ ^a ^b ^c ^d ^e Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R (September 2008). "The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?". Am. J. Obstet. Gynecol. 199 (3): 215–23. doi:10.1016/j.ajog.2008.04.009. PMID 18468571.
^ Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow RE (December 2005). "Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range". J. Clin. Oncol. 23 (36): 9338–43. doi:10.1200/JCO.2005.02.2582. PMID 16361633.
^ E L Moss, J Hollingworth, T M Reynolds (September 2004). "The role of CA125 in clinical practice". J. Clin. Pathol. 58 (3): 308–312. doi:10.1136/jcp.2004.018077. PMID 15735166.
^ Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R (September 2008). "Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre". Ir Med J 101 (8): 245–7. PMID 18990955.
^ Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998). "CA 125: the past and the future". Int. J. Biol. Markers 13 (4): 179–87. PMID 10228898.
^ Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M (January 2008). "Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax". Eur. Respir. J. 31 (1): 140–2. doi:10.1183/09031936.00094206. PMID 17804443.
^ Sarandakou A, Protonotariou E, Rizos D (2007). "Tumor markers in biological fluids associated with pregnancy". Crit Rev Clin Lab Sci 44 (2): 151–78. doi:10.1080/10408360601003143. PMID 17364691.
^ Asher V, Hammond R, Duncan TJ (2010). "Pelvic mass associated with raised CA 125 for benign condition: a case report". World J Surg Oncol 8: 28. doi:10.1186/1477-7819-8-28. PMC 2861664. PMID 20398372.
^ Faulkner D, Meldrum C (2012). "Tumour markers". Australian Prescriber 35 (4): 125–8.
^ Ferrini R (1997). "Screening asymptomatic women for ovarian cancer: American College of Preventive Medicine practice policy". Am J Prev Med 13 (6): 444–6. PMID 9415790.
^ Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC (November 2005). "Potential markers that complement expression of CA125 in epithelial ovarian cancer". Gynecol. Oncol. 99 (2): 267–77. doi:10.1016/j.ygyno.2005.06.040. PMID 16061277.
^ Sasaroli D, Coukos G, Scholler N (June 2009). "Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?". Biomark Med 3 (3): 275–288. doi:10.2217/bmm.09.21. PMC 2726755. PMID 19684876.
^ Patankar MS, Jing Y, Morrison JC, Belisle JA, Lattanzio FA, Deng Y, Wong NK, Morris HR, Dell A, Clark GF (December 2005). "Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125". Gynecol. Oncol. 99 (3): 704–13. doi:10.1016/j.ygyno.2005.07.030. PMID 16126266.
^ Seelenmeyer C, Wegehingel S, Lechner J, Nickel W (April 2003). "The cancer antigen CA125 represents a novel counter receptor for galectin-1". J. Cell. Sci. 116 (Pt 7): 1305–18. PMID 12615972.
^ Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (March 2004). "Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion". J. Biol. Chem. 279 (10): 9190–8. doi:10.1074/jbc.M312372200. PMID 14676194.
^ ^a ^b Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS (2006). "Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors". Mol. Cancer 5 (1): 50. doi:10.1186/1476-4598-5-50. PMC 1635730. PMID 17067392.
^ Chang K, Pastan I (January 1996). "Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers". Proc. Natl. Acad. Sci. U.S.A. 93 (1): 136–40. doi:10.1073/pnas.93.1.136. PMC 40193. PMID 8552591.
^ Thériault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piché A, Rancourt C (June 2011). "MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis". Gynecol. Oncol. 121 (3): 434–43. doi:10.1016/j.ygyno.2011.02.020. PMID 21421261.
^ Boivin M, Lane D, Piché A, Rancourt C (December 2009). "CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis". Gynecol. Oncol. 115 (3): 407–13. doi:10.1016/j.ygyno.2009.08.007. PMID 19747716.
^ Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (November 1981). "Reactivity of a monoclonal antibody with human ovarian carcinoma". J. Clin. Invest. 68 (5): 1331–7. doi:10.1172/JCI110380. PMC 370929. PMID 7028788.
^ Schmidt C (August 2011). "CA-125: a biomarker put to the test. Journal of the National Cancer Institute". J. Natl. Cancer Inst. 103 (17): 1290–1. doi:10.1093/jnci/djr344. PMID 21852262.

External links[edit]

CA-125 blood test urban legend at snopes.com
CA-125 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH)
CA-125 at Lab Tests Online
CA-125 analyte monograph from The Association for Clinical Biochemistry and Laboratory Medicine.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 上皮性卵巣癌、卵管癌、または原発性腹膜癌患者の付属器腫瘤の評価のための血清バイオマーカー serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary fallopian tube or peritoneum
2. 卵巣癌のスクリーニング screening for ovarian cancer
3. 上皮性卵巣癌、卵管癌、または腹膜癌生存者へのアプローチの概要 overview of the approach to survivors of epithelial ovarian fallopian tube or peritoneal carcinomas
4. 付属器腫瘤のマネージメント management of an adnexal mass
5. 上皮性卵巣癌、卵管癌、および腹膜癌の概要 overview of epithelial carcinoma of the ovary fallopian tube and peritoneum

English Journal

Market surveillance of in vitro diagnostics by the BfArM until end 2010: how safe are products for tumor diagnostics?

Siekmeier R, Wetzel D.SourceDepartment of Medical Products, Federal Institute for Drugs and Medical Devices, Bonn, Germany. Ruediger.Siekmeier@bfarm.de
Advances in experimental medicine and biology.Adv Exp Med Biol.2013;755:385-96.
The European Directive 98/79/EC on in vitro diagnostic medical devices (IVD) regulates the marketing and post market surveillance of IVD in the European Economic Area. In cases of incidents and field corrective actions the manufacturers have to inform the responsible Competent Authorities (CA). In G
PMID 22826091

Clinical, histologic, and genetic features of mesothelioma in a 7-Year-old child.

Sugalski A, Davis M, Prasannan L, Saldivar V, Hung JY, Tomlinson GE.SourceDepartment of Pediatrics and Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Pediatric blood & cancer.Pediatr Blood Cancer.2013 Jan;60(1):146-8. doi: 10.1002/pbc.24284. Epub 2012 Sep 7.
Malignant mesothelioma (MM) is a highly aggressive malignancy that is extremely rare in children. This case report documents a 7-year-old male without previous asbestos exposure with peritoneal MM that initially responded to chemotherapy with cisplatin and gemcitabine but ultimately metastasized to
PMID 22961710

Japanese Journal

The Pretreatment of Maximum Standardized Uptake Values (SUVmax) of the Primary Tumor Is Predictor for Poor Prognosis for Patients with Epithelial Ovarian Cancer

Nakamura Keiichiro,Hongo Atsushi,Kodama Junichi,Hiramatsu Yuji
Acta Medica Okayama 66(1), 53-60, 2012-02
… We found that the pretreatment values of maximum standardized uptake (SUVmax) of the primary tumor by positron emission tomography/computed tomography (PET/CT), tumor marker CA125 and C-reactive protein (CRP) were correlated with clinical characteristics and prognosis for such patients. … The clinical parameters and prognoses and their correlations with SUVmax of primary tumor, CA125 and CRP were examined for 51 patients with primary ovarian cancer. …
NAID 120003850608

Usefulness of tumor marker CA-125 serum levels for the follow-up of therapeutic responses in tuberculosis patients with and without serositis

Huang Wei-Chang,Tseng Chih-Wei,Chang Kai-Ming [他]
Japanese Journal of Infectious Diseases 64(5), 367-372, 2011-09
NAID 40019008825

Related Pictures

★リンクテーブル★

リンク元	「CA125」
関連記事	「C」「CA」

「CA125」

Mucin 16, cell surface associated
	; Ovarian Cancer - Basic Science Perspective
Identifiers
Symbols	MUC16; CA125
External IDs	OMIM: 606154 HomoloGene: 133291 GeneCards: MUC16 Gene
Gene Ontology
Molecular function	• protein binding;
Cellular component	• extracellular space; • Golgi lumen; • plasma membrane; • integral to membrane; • extrinsic to membrane;
Biological process	• cell adhesion; • O-glycan processing; • post-translational protein modification; • cellular protein metabolic process;
	Sources: Amigo / QuickGO
Orthologs
	This box: view; talk; edit;

　　[★]

同: 糖鎖抗原125 carbohydrateantigen 125, CA-125
関: 肺癌、腫瘍マーカー

概念

肺の腺癌で陽性率が約50%。CA125は漿膜細胞からも産生されるので、漿水診断で良性・悪性を判断できない (SPU.327)
子宮内膜症で陽性となることがある。Re-AFS分類による陽性率は1-2期：30%, 3期：50%, 4期：約75%。(NGY.196)

CA125：卵巣癌(漿液性嚢胞腺癌、粘液性嚢胞腺癌)、子宮頚癌、子宮体癌

ヒト培養卵巣癌細胞に見いだされた抗原

卵巣癌の腫瘍マーカーとして用いられる(陽性率60-80%)
組織型によって陽性率が異なる(漿液性嚢胞腺癌 > 粘液性嚢胞腺癌)

診断、治療効果の評価、再発のモニターなどに有用

CA125が陽性となりうる疾患

(腫瘍性)卵巣癌(漿液性嚢胞腺癌、粘液性嚢胞腺癌)、子宮頚癌、子宮体癌、胃癌、結腸癌、肺癌、癌腹膜転移、良性卵巣腫瘍、肝癌、胆道癌、膵癌
(非腫瘍性)子宮内膜症、子宮筋腫、腹膜炎、胸膜炎、妊娠初期(12週まで)、月経期、産褥期

基準値

HIM.A-4

0-35 U/ml

基準値の本

男性、閉経後女性：＜25 U/ml
閉経前女性：＜40 U/ml

「C」

　　[★]

炭素 carbon
シトシン cytosine
システイン cysteine
シチジン
セルシウス度摂氏 degrees Celsius degree C
産婦人科領域で「子宮外頚子宮外頚部 exocervix」を表現するための略語

「CA」

　　[★]

[pmid11369781-1] Yin BW, Lloyd KO (July 2001). "Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16". J. Biol. Chem. 276 (29): 27371–5. doi:10.1074/jbc.M103554200. PMID 11369781.

[pmid11920644-2] Yin BW, Dnistrian A, Lloyd KO (April 2002). "Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene". Int. J. Cancer 98 (5): 737–40. doi:10.1002/ijc.10250. PMID 11920644.

[pmid16500040-3] Duraisamy S, Ramasamy S, Kharbanda S, Kufe D (May 2006). "Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16". Gene 373: 28–34. doi:10.1016/j.gene.2005.12.021. PMID 16500040.

[pmid10228898-4] Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998). "CA 125: the past and the future". Int. J. Biol. Markers 13 (4): 179–87. PMID 10228898.

[pmid17898256-5] Gipson IK (October 2007). "The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture". Invest. Ophthalmol. Vis. Sci. 48 (10): 4390; 4391–8. doi:10.1167/iovs.07-0770. PMC 2886589. PMID 17898256.

[pmid22339855-6] Gniewek P, Kolinski A (January 2012). "Coarse-Grained Modeling of Mucus Barrier Properties". Biophys. J. 102 (2): 195–200. doi:10.1016/j.bpj.2011.11.4010. ISSN 0006-3495. PMID 22339855.

[pmid11786729-7] O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L (Nov–Dec 2001). "The CA 125 gene: an extracellular superstructure dominated by repeat sequences". Tumour Biol. 22 (6): 348–66. doi:10.1159/000050638. PMID 11786729.

[pmid14681689-8] Hollingsworth MA, Swanson BJ (January 2004). "Mucins in cancer: protection and control of the cell surface". Nat. Rev. Cancer 4 (1): 45–60. doi:10.1038/nrc1251. PMID 14681689.

[pmid19935676-9] Kufe DW (December 2009). "Mucins in cancer: function, prognosis and therapy". Nat. Rev. Cancer 9 (12): 874–85. doi:10.1038/nrc2761. PMC 2951677. PMID 19935676.

[pmid19538730-10] Goodell CA, Belisle JA, Gubbels JA, Migneault M, Rancourt C, Connor J, Kunnimalaiyaan M, Kravitz R, Tucker W, Zwick M, Patankar MS (2009). "Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies". J Ovarian Res 2 (1): 8. doi:10.1186/1757-2215-2-8. PMC 2708168. PMID 19538730.

[pmid15943821-11] Palmai-Pallag T, Khodabukus N, Kinarsky L, Leir SH, Sherman S, Hollingsworth MA, Harris A (June 2005). "The role of the SEA (sea urchin sperm protein, enterokinase and agrin) module in cleavage of membrane-tethered mucins". FEBS J. 272 (11): 2901–11. doi:10.1111/j.1742-4658.2005.04711.x. PMID 15943821.

[pmid18289532-12] Perez BH, Gipson IK (November 2008). "Focus on Molecules: human mucin MUC16". Exp. Eye Res. 87 (5): 400–1. doi:10.1016/j.exer.2007.12.008. PMC 2586928. PMID 18289532.

[pmid17898272-13] Blalock TD, Spurr-Michaud SJ, Tisdale AS, Heimer SR, Gilmore MS, Ramesh V, Gipson IK (October 2007). "Functions of MUC16 in corneal epithelial cells". Invest. Ophthalmol. Vis. Sci. 48 (10): 4509–18. doi:10.1167/iovs.07-0430. PMID 17898272.

[pmid20348949-14] Bafna S, Kaur S, Batra SK (May 2010). "Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells". Oncogene 29 (20): 2893–904. doi:10.1038/onc.2010.87. PMC 2879972. PMID 20348949.

[pmid21080822-15] Suh KS, Park SW, Castro A, Patel H, Blake P, Liang M, Goy A (November 2010). "Ovarian cancer biomarkers for molecular biosensors and translational medicine". Expert Rev. Mol. Diagn. 10 (8): 1069–83. doi:10.1586/erm.10.87. PMID 21080822.

[ACOGfive-16] American Congress of Obstetricians and Gynecologists, "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American Congress of Obstetricians and Gynecologists), retrieved August 1, 2013 , which cites

"Screening for Ovarian Cancer: Recommendation Statement". The Annals of Family Medicine 2 (3): 260–262. 2004. doi:10.1370/afm.200. edit

Lin, Kenneth; Barton, Mary B. (April 2012), "Screening for Ovarian Cancer - Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement", AHRQ Publication No. 12-05165-EF-3 (United States Preventive Services Task Force), retrieved 30 August 2013

Partridge, E.; Greenlee, A. R.; Xu, R. T.; Kreimer, C.; Williams, J. L.; Riley, T. R.; Reding, B.; Church, C. C.; Kessel, J. L.; Johnson, C.; Hill, G. L.; Fouad, S.; Buys, L. R.; Isaacs, S. S.; Andriole, T.; Ogden, S.; Chia, D.; Ragard, L. R.; Prorok, P. C.; Gohagan, J. K.; Berg, C. D. (2009). "Results from four rounds of ovarian cancer screening in a randomized trial". Obstetrics and gynecology 113 (4): 775–782. doi:10.1097/AOG.0b013e31819cda77. PMC 2728067. PMID 19305319. edit

American College of Obstetricians; Gynecologists Committee on Gynecologic Practice (2011). "Committee Opinion No. 477: The Role of the Obstetrician–Gynecologist in the Early Detection of Epithelial Ovarian Cancer". Obstetrics & Gynecology 117 (3): 742–746. doi:10.1097/AOG.0b013e31821477db. PMID 21343791. edit

[17] "Screening for Ovarian Cancer: Recommendation Statement". The Annals of Family Medicine 2 (3): 260–262. 2004. doi:10.1370/afm.200. edit

[18] Lin, Kenneth; Barton, Mary B. (April 2012), "Screening for Ovarian Cancer - Evidence Update for the U.S. Preventive Services Task Force Reaffirmation Recommendation Statement", AHRQ Publication No. 12-05165-EF-3 (United States Preventive Services Task Force), retrieved 30 August 2013

[19] Partridge, E.; Greenlee, A. R.; Xu, R. T.; Kreimer, C.; Williams, J. L.; Riley, T. R.; Reding, B.; Church, C. C.; Kessel, J. L.; Johnson, C.; Hill, G. L.; Fouad, S.; Buys, L. R.; Isaacs, S. S.; Andriole, T.; Ogden, S.; Chia, D.; Ragard, L. R.; Prorok, P. C.; Gohagan, J. K.; Berg, C. D. (2009). "Results from four rounds of ovarian cancer screening in a randomized trial". Obstetrics and gynecology 113 (4): 775–782. doi:10.1097/AOG.0b013e31819cda77. PMC 2728067. PMID 19305319. edit

[20] American College of Obstetricians; Gynecologists Committee on Gynecologic Practice (2011). "Committee Opinion No. 477: The Role of the Obstetrician–Gynecologist in the Early Detection of Epithelial Ovarian Cancer". Obstetrics & Gynecology 117 (3): 742–746. doi:10.1097/AOG.0b013e31821477db. PMID 21343791. edit

[pmid21176210-17] Gupta D, Lis CG (2010). "Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature". Nutr J 9: 69. doi:10.1186/1475-2891-9-69. PMC 3019132. PMID 21176210.

[pmid6310399-18] Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (October 1983). "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". N. Engl. J. Med. 309 (15): 883–7. doi:10.1056/NEJM198310133091503. PMID 6310399.

[pmid8479736-19] Göcze P, Vahrson H (April 1993). "[Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)]". Orv Hetil (in Hungarian) 134 (17): 915–8. PMID 8479736.

[pmid16361633-20] Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow RE (December 2005). "Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range". J. Clin. Oncol. 23 (36): 9338–43. doi:10.1200/JCO.2005.02.2582. PMID 16361633.

[isbn0-89189-579-5-21] Mais DD, Leonard GR (2009). Quick Compendium Companion for Clinical Pathology (2nd ed.). Chicago: American Society for Clinical Pathology. p. 352. ISBN 0-89189-579-5.

[urlWomen_should_be_offered_a_blood_test_for_ovarian_cancer-22] "Women should be offered a blood test for ovarian cancer". NICE guidance. United Kingdom National Institute for Health and Clinical Excellence. 2011-04-27. Retrieved 2012-04-14.

[pmid19585675-23] Wang ML, Huang Q, Yang T (July 2009). "IgE myeloma with elevated level of serum CA125". J Zhejiang Univ Sci B. 10 (7): 559–562. doi:10.1631/jzus.B0820399. PMC 2704975. PMID 19585675.

[pmid22495319-24] Baron, JA (May 2012). "Screening for cancer with molecular markers: progress comes with potential problems". Nat. Rev. Cancer 12 (5): 1379–80. doi:10.1038/nrc3260. PMID 22495319.

[pmid9665412-25] Fritsche HA, Bast RC (July 1998). "CA 125 in ovarian cancer: advances and controversy". Clin. Chem. 44 (7): 1379–80. PMID 9665412.

[pmid18468571-26] Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R (September 2008). "The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?". Am. J. Obstet. Gynecol. 199 (3): 215–23. doi:10.1016/j.ajog.2008.04.009. PMID 18468571.

[autogenerated1-27] Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, Bristow RE (December 2005). "Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range". J. Clin. Oncol. 23 (36): 9338–43. doi:10.1200/JCO.2005.02.2582. PMID 16361633.

[pmid15735166-28] E L Moss, J Hollingworth, T M Reynolds (September 2004). "The role of CA125 in clinical practice". J. Clin. Pathol. 58 (3): 308–312. doi:10.1136/jcp.2004.018077. PMID 15735166.

[pmid18990955-29] Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R (September 2008). "Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre". Ir Med J 101 (8): 245–7. PMID 18990955.

[autogenerated2-30] Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB (1998). "CA 125: the past and the future". Int. J. Biol. Markers 13 (4): 179–87. PMID 10228898.

[pmid17804443-31] Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M (January 2008). "Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax". Eur. Respir. J. 31 (1): 140–2. doi:10.1183/09031936.00094206. PMID 17804443.

[pmid17364691-32] Sarandakou A, Protonotariou E, Rizos D (2007). "Tumor markers in biological fluids associated with pregnancy". Crit Rev Clin Lab Sci 44 (2): 151–78. doi:10.1080/10408360601003143. PMID 17364691.

[pmid20398372-33] Asher V, Hammond R, Duncan TJ (2010). "Pelvic mass associated with raised CA 125 for benign condition: a case report". World J Surg Oncol 8: 28. doi:10.1186/1477-7819-8-28. PMC 2861664. PMID 20398372.

[34] Faulkner D, Meldrum C (2012). "Tumour markers". Australian Prescriber 35 (4): 125–8.

[pmid9415790-35] Ferrini R (1997). "Screening asymptomatic women for ovarian cancer: American College of Preventive Medicine practice policy". Am J Prev Med 13 (6): 444–6. PMID 9415790.

[pmid16061277-36] Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC (November 2005). "Potential markers that complement expression of CA125 in epithelial ovarian cancer". Gynecol. Oncol. 99 (2): 267–77. doi:10.1016/j.ygyno.2005.06.040. PMID 16061277.

[pmid19684876-37] Sasaroli D, Coukos G, Scholler N (June 2009). "Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?". Biomark Med 3 (3): 275–288. doi:10.2217/bmm.09.21. PMC 2726755. PMID 19684876.

[pmid16126266-38] Patankar MS, Jing Y, Morrison JC, Belisle JA, Lattanzio FA, Deng Y, Wong NK, Morris HR, Dell A, Clark GF (December 2005). "Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125". Gynecol. Oncol. 99 (3): 704–13. doi:10.1016/j.ygyno.2005.07.030. PMID 16126266.

[pmid12615972-39] Seelenmeyer C, Wegehingel S, Lechner J, Nickel W (April 2003). "The cancer antigen CA125 represents a novel counter receptor for galectin-1". J. Cell. Sci. 116 (Pt 7): 1305–18. PMID 12615972.

[pmid14676194-40] Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (March 2004). "Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion". J. Biol. Chem. 279 (10): 9190–8. doi:10.1074/jbc.M312372200. PMID 14676194.

[pmid17067392-41] Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS (2006). "Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors". Mol. Cancer 5 (1): 50. doi:10.1186/1476-4598-5-50. PMC 1635730. PMID 17067392.

[pmid8552591-42] Chang K, Pastan I (January 1996). "Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers". Proc. Natl. Acad. Sci. U.S.A. 93 (1): 136–40. doi:10.1073/pnas.93.1.136. PMC 40193. PMID 8552591.

[pmid21421261-43] Thériault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piché A, Rancourt C (June 2011). "MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis". Gynecol. Oncol. 121 (3): 434–43. doi:10.1016/j.ygyno.2011.02.020. PMID 21421261.

[pmid19747716-44] Boivin M, Lane D, Piché A, Rancourt C (December 2009). "CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis". Gynecol. Oncol. 115 (3): 407–13. doi:10.1016/j.ygyno.2009.08.007. PMID 19747716.

[pmid7028788-45] Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (November 1981). "Reactivity of a monoclonal antibody with human ovarian carcinoma". J. Clin. Invest. 68 (5): 1331–7. doi:10.1172/JCI110380. PMC 370929. PMID 7028788.

[pmid21852262-46] Schmidt C (August 2011). "CA-125: a biomarker put to the test. Journal of the National Cancer Institute". J. Natl. Cancer Inst. 103 (17): 1290–1. doi:10.1093/jnci/djr344. PMID 21852262.

匿名

検索

案内

案内

CA-125